Publicacions (76) Publicacions de Juan Luis Gómez Sirvent

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

    Clinical Microbiology and Infection, Vol. 29, Núm. 1, pp. 85-93

  3. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

    Journal of Medical Virology, Vol. 95, Núm. 12

2022

  1. Detection of Unknown Defects in Semiconductor Materials from a Hybrid Deep and Machine Learning Approach

    Bio-inspired Systems and Applications: from Robotics to Ambient Intelligence: 9th International Work-Conference on the Interplay Between Natural and Artificial Computation, IWINAC 2022, Puerto de la Cruz, Tenerife, Spain, May 31 – June 3, 2022, Proceedings, Part II (Springer Suiza), pp. 356-365

  2. Vancomicina frente a daptomicina como tratamiento de las bacteriemias asociadas a catéter y causadas por grampositivos en el paciente oncológico

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 3, pp. 105-108

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

    Trials, Vol. 22, Núm. 1

2020

  1. Psychological distress in women and men living with HIV in Spain: a cross-sectional telephone survey

    Evidence-based mental health, Vol. 23, Núm. 3, pp. 91-99

  2. Sexual behaviour and poor hygiene are related to recent hepatitis a virus community outbreaks

    Revista Española de Enfermedades Digestivas, Vol. 112, Núm. 6, pp. 448-455

  3. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300

  4. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362

  2. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  3. ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1763-1770

  4. HTLV testing of solid organ transplant donors

    Clinical Transplantation

  5. HTLV-1 infection in solid organ transplant donors and recipients in Spain

    BMC Infectious Diseases, Vol. 19, Núm. 1

  6. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663